Gene · 1870
E2F2: E2F transcription factor 2
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. E2F2: E2F transcription factor 2. Genes, record 1870. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/1870
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q14209 | Transcription factor E2F2 | 437 | 1 | Ensembl, GeneID, HGNC |
Source UniProt
Patents32
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 44616 | Q14209 | Espacenet |
| WO 2025235563 A1 | 2025-11-13 | 30 | Q14209 | Espacenet |
| EP 4641202 A2 | 2025-10-29 | 5354 | Q14209 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 14905 | Q14209 | Espacenet |
| JP 2025028160 A | 2025-02-28 | 14905 | Q14209 | Espacenet |
| KR 1020250017231 A | 2025-02-04 | 5354 | Q14209 | Espacenet |
| KR 1020250010750 A | 2025-01-21 | 14905 | Q14209 | Espacenet |
| JP 2024109657 A | 2024-08-14 | 14744 | Q14209 | Espacenet |
| US 11708396 B2 | 2023-07-25 | 2202 | Q14209 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 26387 | Q14209 | Espacenet |
1 to 10 of 32
See all 32 patentsDrugs2
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
Trials0
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
None in this release.
NIH grants1,762
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | E2F2 papers | Newest fiscal year |
|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 22 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 11 | 2025 |
| P30CA076292 | Moffitt Cancer Center Support Grant | 9 | 2025 |
| UL1TR001863 | Yale Clinical and Translational Science Award | 9 | 2025 |
| P30CA068485 | Cancer Center Support Grant | 8 | 2025 |
| P30CA125123 | Baylor College of Medicine Cancer Center - Cancer Center Support Grant | 8 | 2025 |
| P30CA016359 | Cancer Center Support Grant | 7 | 2025 |
| P30CA015083 | Mayo Clinic Comprehensive Cancer Center Support Grant | 6 | 2025 |
| P30CA016058 | Cancer Center Support Grant | 5 | 2025 |
| P30CA056036 | Translational Research in Cancer | 5 | 2025 |
1 to 10 of 1,762Source NIH's project files
See all 1,762 nih grantsPapers2,847
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| METTL3-mediated m⁶A methylation of E2F2 targets MCU to promote the malignant phenotype of gastric cancer cells. | Cancer Gene Ther | 2026 | 42823456 | PubTator, text mining | PubMed |
| Subtype-Dependent Transcriptional Coupling Between DNMT1 and E2F-Linked Proliferative Programs in Breast Cancer: A Dual-Cohort Transcriptomic Analysis. | J Cancer | 2026 | 42741635 | PubTator, text mining | PubMed |
| Identification of a nuclear transcriptional module associated with ERα and E2F/FOXM1 signaling across PAM50 breast cancer subtypes. | Front Oncol | 2026 | 42620280 | PubTator, text mining | PubMed |
| Integrative single-nucleus transcriptomic analysis identifies UBE2C+ proliferative tumor cells and immune-stromal regulatory crosstalk in small cell lung cancer. | Front Immunol | 2026 | 42614523 | PubTator, text mining | PubMed |
| Cordycepin inhibits pancreatic cancer progression and enhances gemcitabine sensitivity by targeting the CDK2/E2F2 axis to modulate TNNI2 expression. | Biochem Pharmacol | 2026 | 42526773 | PubTator, text mining | PubMed |
| DYRK1A Signaling in the Brain: Molecular Mechanisms and Neurotransmitter Regulation. | Curr Neurovasc Res | 2026 | 42405393 | PubTator, text mining | PubMed |
| Azacytidine restores T cell function in AML by modulating DNA methylation. | bioRxiv | 2026 | 42367853 | PubTator, text mining | PubMed |
| Hepatitis C virus inhibits the E2F2/PI3K/AKT signaling pathway through miR-378b and leads to glycolipid metabolism disorders in the liver. | Mol Biol Rep | 2026 | 42283974 | PubTator, text mining | PubMed |
| Modeling stimulus-induced stress responses in microglia-like cells using a commercial iPSC-dCas9-KRAB line. | Stem Cell Res | 2026 | 42214129 | PubTator, text mining | PubMed |
| Balancing osteogenesis and adipogenesis in osteogenesis imperfecta: PLIN2 and E2F2 as key targets for mesenchymal stem cell therapy. | Adv Clin Exp Med | 2026 | 42186939 | PubTator, text mining | PubMed |
1 to 10 of 2,847
See all 2,847 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/1870
GET https://conductscience.org/api/genes/v1/1870/patents?page=2